Tesamorelin is an FDA-approved prescription drug (brand name Egrifta), cleared in 2010 on the strength of multiple Phase 3 double-blind, placebo-controlled randomized trials for a specific, narrow indication: reducing excess abdominal fat in people with HIV-associated lipodystrophy
A 0.5 mg dose is 10 units on an insulin syringe
,
For Vitamins (12 Tablets): Diluent (INS 460 (i)), Inositol, L-Ascorbic Acid, Diluent (INS 341 (ii)), DL-Alpha Tocopheryl Acetate, Niacinamide, Vehicle (INS 1521), Coating Agent (INS 464), Binder (INS 1201), Disintegrant (Sodium Starch Glycolate), Cholecalciferol, Glidant (INS 553 (iii)), Antisticking Agent (INS 470 (iii)), Retinyl Acetate, Calcium Pantothenate, Colour (Titanium dioxide coated mica pearlescent pigments and iron oxide), Anticaking Agent (Magnesium Aluminometasilicate), Pyridoxine Hydrochloride, Thiamine Mononitrate, Coating Agent (INS 462), Colours (INS 110), N-Phenyl-L-Glutamic Acid, Colour (INS 100), D-Biotin, Methylcobalamin, Beta Sitosterol
What years does this Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market cover, and what was the market size in 2025
